【6月文獻(xiàn)戰(zhàn)報(bào)】Bioss抗體新增高分文獻(xiàn)精彩呈現(xiàn)

更新時(shí)間：2022-07-28 | 點(diǎn)擊率：1839

截至目前，引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)共18868篇，總影響因子82731.02分，發(fā)表在Nature, Science, Cell以及Immunity等頂級(jí)期刊的文獻(xiàn)共53篇，合作單位覆蓋了清華、北大、復(fù)旦、華盛頓大學(xué)、麻省理工學(xué)院、東京大學(xué)以及紐約大學(xué)等國(guó)際研究機(jī)構(gòu)上百所。

我們每月收集引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)。若您在當(dāng)月已發(fā)表SCI文章，但未被我公司收集，請(qǐng)致電Bioss，我們將贈(zèng)予現(xiàn)金鼓勵(lì)，金額標(biāo)準(zhǔn)請(qǐng)參考“發(fā)文章領(lǐng)獎(jiǎng)金”活動(dòng)頁(yè)面。

近期收錄2022年6月引用Bioss產(chǎn)品發(fā)表的文獻(xiàn)共227篇（圖一，綠色柱），文章影響因子(IF) 總和高達(dá)1231.317，其中，10分以上文獻(xiàn)15篇（圖二）。

圖一

圖二

本文主要分享引用Bioss產(chǎn)品發(fā)表文章至Nature Nanotechnology, Immunity, Cancer Cell等期刊的7篇IF＞10的文獻(xiàn)摘要，讓我們一起欣賞吧。

CHEMICAL ENGINEERING JOURNAL

[IF=13.273]

文獻(xiàn)引用抗體：

bs-0061R

Anti-beta-Actin(Loading Control) pAb

bs-4511R

Anti-beta tubulin(Loading Control) pAb

作者單位：北京大學(xué)藥物科學(xué)學(xué)院

摘要：Most cancers recur after clinical treatment. Activation of the patient's own immunity can not only play a therapy role, but also consolidate the treatment prognosis. However, an effective immunity reconstruction strategy remains an impeding issue to be solved. Here, we report a macrophage immunity reconstruction strategy by engineering the stem cell biomimetic liposomes that carry levamisole (sLipo leva) to treat leukemia. The results demonstrated that sLipo leva was successfully constructed by incorporating the membrane of mesenchymal stem cells (MSCs). sLipo leva displayed a significant targeting effect on macrophages, induced the differentiation of them into M1 phenotype, exhibited a robust anticancer efficacy and an acceptable safety in leukemia-bearing mice. The immunity reconstruction mechanism of sLipo leva could be explained by two aspects: activation of macrophages themselves, and further activation of T cells, both of which contributed to the killing of leukemia cells. In conclusion, the present study offers a promising new strategy to activate the patient's own immunity for playing therapy efficacy and for consolidating treatment prognosis of leukemia.

CHEMICAL ENGINEERING JOURNAL

[IF=13.273]

文獻(xiàn)引用抗體：bs-2558R

Anti-EGFRvIII pAb

作者單位：香港城市大學(xué)材料科學(xué)與工程系

摘要：Glioblastoma (GBM) is an incurable brain tumor in which hypoxic GBM cells (GMs) increase the production and release of exosomes, which are 30–200 nm vesicles crossing the blood–brain-barrier, enabling exosomal biomarkers to be promising targets for the tracking of GBM malignancy. Here, a localized surface plasmon resonance (LSPR) sensor chip was developed to detect an infinitesimal amount of exosomal biomarkers. Self-assembly silver nanoparticles decorated on gold nano-islands (Ag@AuNIs) sensor chip was used to provide site-specific bio-conjunction of biotinylated antibodies for detection of exosomal surface biomarkers. The biotinylated antibody functionalized (BAF) Ag@AuNIs LSPR biosensor sensitively detected cluster of differentiation 63, an exosome marker, and monocarboxylate transporter 4 (MCT4), a GBM progression biomarker, in malignant GMs-derived exosomes in the dynamic range of 3.8 × 10⁻⁴ to 50 μg/ml with limit of detection (LOD) of 0.38 ng/ml and 1.4 × 10⁻³ to 500 μg/ml with LOD of 1.4 ng/ml, respectively. Furthermore, it detected the enhanced level of MCT4 in malignant hypoxic GMs-derived exosomes as well as increased MCT4 in the blood serum-derived exosomes of GBM mice in the dynamic range of 4 × 10⁻⁴ to 50 μg/ml with LOD of 0.4 ng/ml. Finally, it could quantify MCT4 in the isolated GMs-derived exosomes from the blood of GBM mice by epidermal growth factor receptor variant III-based immunocapture, suggesting its utility for minimally-invasive monitoring of GBM progression as liquid biopsy. With excellent attributes of high sensitivity and selectivity in label-free sensing for exosomal biomarkers, the BAF Ag@AuNIs LSPR biosensor has great potential for early detection of GBM formation and progression.

BIOMATERIALS [IF=12.479]

文獻(xiàn)引用抗體：

bs-0028R ; Anti-GSK-3 Beta pAb; WB

bs-0061R ; Anti-beta-Actin (Loading Control) pAb; WB

bs-14519R ; Anti-phospho-eIF2B epsilon (Ser539) pAb; WB

bs-14533R ; Anti-eIF2B epsilon pAb; WB

bs-17330R ; Anti-hnRNP A1 pAb; WB

bs-20611R ; Anti-PI 3 Kinase p85 alpha pAb; WB

bs-23217R ; Anti-NFKB p65 pAb; WB

bsm-33278M ; Mouse Anti-AKT mAb; WB

bs-0295P-HRP ; Rabbit IgG/HRP; WB

bs-0805R ; Anti-CD56 pAb

bs-0832R ; Anti-MICA pAb

bs-0938R ; Anti-NKG2D pAb

bs-1214R ; Anti-TRAIL pAb

bs-2411R ; Anti-NKG2A pAb

bs-2420R ; Anti-NCR2 pAb

bs-2569R ; Anti-CD226 pAb

bs-6028R ; Anti-CD16 pAb

bs-6874R ; Anti-Catalase pAb

bs-20399R ; Anti-HIF-1 Alpha pAb

bs-41214R ; Anti-NCR1 pAb

bs-0295G-AF594 ; Goat Anti-Rabbit IgG H&L/Alexa Fluor 594

作者單位：北京理工大學(xué)生命科學(xué)學(xué)院

摘要：Natural killer cells (NKs) hold great promise in cancer treatment, but their application in solid tumors remains a great challenge because current solutions hardly can overcome various difficulties that faced. Herein, we endow NKs with the phytochemical feature for effective immunotherapy of solid tumors. NKs are decorated with natural thylakoid (Tk) membranes through an efficient and convenient membrane fusion strategy. Tk engineering effectively activates NKs, because the antioxidase on Tk induce glycogen synthase kinase-3β inhibition, and subsequently increase the expression of activating receptor and cytotoxic effector molecules in NKs. After systemic administration, the phytochemical NKs (PC-NKs) can target tumor tissues, and then profoundly reprogram tumor microenvironment (TME) with the help of catalase on Tk, resulting in significantly enhanced direct killing of PC-NKs and immune activated TME. Therefore, potent therapeutic effects with few abnormalities are achieved, providing a novel idea for the development of highly efficient NKs for solid tumors.

Redox Biology [IF=11.799]

文獻(xiàn)引用抗體：bs-6313R

Anti-4 Hydroxynonenal pAb

作者單位：日本熊本大學(xué)藥理學(xué)研究生院生物制藥學(xué)系

摘要：Renal ischemia-reperfusion (IR)-induced tissue hypoxia causes impaired energy metabolism and oxidative stress. These conditions lead to tubular cell damage, which is a cause of acute kidney injury (AKI) and AKI to chronic kidney disease (CKD). Three key molecules, i.e., hypoxia-inducible factor-1α (HIF-1α), AMP-activated protein kinase (AMPK), and nuclear factor E2-related factor 2 (Nrf2), have the potential to protect tubular cells from these disorders. Although carbon monoxide (CO) can comprehensively induce these three molecules via the action of mitochondrial reactive oxygen species (mtROS), the issue of whether CO induces these molecules in tubular cells remains unclear. Herein, we report that CO-enriched red blood cells (CO-RBC) cell therapy, the inspiration for which is the in vivo CO delivery system, exerts a renoprotective effect on hypoxia-induced tubular cell damage via the upregulation of the above molecules. Experiments using a mitochondria-specific antioxidant provide evidence to show that CO-driven mtROS partially contributes to the upregulation of the aforementioned molecules in tubular cells. CO-RBC ameliorates the pathological conditions of IR-induced AKI model mice via activation of these molecules. CO-RBC also prevents renal fibrosis via the suppression of epithelial mesenchymal transition and transforming growth factor-β1 secretion in an IR-induced AKI to CKD model mice. In conclusion, our results confirm that the bioinspired CO delivery system prevents the pathological conditions of both AKI and AKI to CKD via the amelioration of hypoxia inducible tubular cell damage, thereby making it an effective cell therapy for treating the progression to CKD.

Redox Biology [IF=11.799]

文獻(xiàn)引用抗體：bs-6313R

Anti-4 Hydroxynonenal pAb

作者單位：韓國(guó)光州昌南國(guó)立大學(xué)醫(yī)學(xué)院內(nèi)科

摘要：The side effects of cisplatin, a widely used chemotherapeutic agent, include nephrotoxicity. Previous studies have reported that cisplatin induces ferroptosis and lipid peroxide accumulation. Ferroptosis, a type of regulated cell death, is characterized by iron-dependent lipid peroxidation. Although previous studies have examined the regulation of ferroptosis in acute kidney injury (AKI), the regulatory mechanism of ferroptosis has not been elucidated. Here, the ability of activated farnesoid X receptor (FXR) to attenuate cisplatin-induced AKI through the regulation of ferroptosis was examined. FXR deficiency exhibited more ferroptosis responses, such as increase in lipid peroxidation, iron content and heme oxygenase 1 protein, and a decrease in glutathione/glutathione disulfide ratio and glutathione peroxidase 4 levels in HK2 cells and mice. Increased blood urea nitrogen, serum creatinine, and ferroptotic responses in the cisplatin-induced AKI mouse model were mitigated upon treatment with the FXR agonist GW4064 but were exacerbated in FXR knockout mice. RNA sequencing analysis revealed that ferroptosis-associated genes were novel targets of FXR. FXR agonist upregulated the expression of lipid and glutathione metabolism-related genes and downregulated cell death-related genes. Additionally, chromatin immunoprecipitation assays, using mice renal tissues, revealed that agonist-activated FXR could bind to its known target genes (Slc51a, Slc51b, Osgin1, and Mafg) and ferroptosis-related genes (Aifm2, Ggt6, and Gsta4). Furthermore, activated FXR-dependent MAFG, a transcriptional repressor, could bind to Hmox1, Nqo1, and Tf in the renal tissues of FXR agonist-treated mice. These findings indicate that activated FXR regulates the transcription of ferroptosis-related genes and protects against cisplatin-induced AKI.

Clinical and Translational Medicine

[IF=11.492]

文獻(xiàn)引用抗體：bs-7552R

Anti-Biglycan pAb; WB

作者單位：復(fù)旦大學(xué)華山醫(yī)院骨科

摘要：Background

Toll-like receptor 4 (TLR4) participates in the initiation of neuroinflammation in various neurological diseases, including central nervous system injuries. NLR family pyrin domain containing 3 (NLRP3) inflammasome-mediated microglial pyroptosis is crucial for the inflammatory response during secondary spinal cord injury (SCI). However, the underlying mechanism by which TLR4 regulates NLRP3 inflammasome activation and microglial pyroptosis after SCI remains uncertain.

Methods

We established an in vivo mouse model of SCI using TLR4-knockout (TLR4-KO) and wild-type (WT) mice. The levels of pyroptosis, tissue damage and neurological function recovery were evaluated in the three groups (Sham, SCI, SCI-TLR4-KO)...

Gut Microbes [IF=10.711]

文獻(xiàn)引用抗體：

bs-2994R

Anti-IRF7 pAb; WB

bsm-34028M

Mouse Anti-ADGRE1 (F4/80) mAb; IHC

作者單位：湖南長(zhǎng)沙中國(guó)科學(xué)院亞熱帶農(nóng)業(yè)研究所亞熱帶地區(qū)農(nóng)業(yè)生態(tài)過(guò)程關(guān)鍵實(shí)驗(yàn)室

摘要：Diarrheal disease is a common health problem with complex causality. Although diarrhea is accompanied by disturbances in microbial diversity, how gut microbes are involved in the occurrence of diarrhea remains largely unknown. Here, using a pig model of post-weaning stress-induced diarrhea, we aim to elucidate and enrich the mechanistic basis of diarrhea. We found significant alterations in fecal microbiome, their metabolites, and microRNAs levels in piglets with diarrhea. Specifically, loss of ssc-miRNA-425-5p and ssc-miRNA-423-3p, which inhibit the gene expression of fumarate reductase (frd) in Prevotella genus, caused succinate accumulation in piglets, which resulted in diarrhea. Single-cell RNA sequencing indicated impaired epithelial function and increased immune response in the colon of piglet with diarrhea. Notably, the accumulated succinate increased colonic fluid secretion by regulating transepithelial Cl-secretion in the epithelial cells. Meanwhile, succinate promoted colonic inflammatory responses by activating MyD88-dependent TLR4 signaling in the macrophages. Overall, our findings expand the mechanistic basis of diarrhea and suggest that colonic accumulation of microbiota-produced succinate caused by loss of miRNAs leads to diarrhea in weanling piglets.

※ 點(diǎn)擊這里查看往期單月Bioss抗體產(chǎn)品文獻(xiàn)引用列表

上一篇：展會(huì)邀請(qǐng)丨Bioss與您相約2022年南昌 CACLP·CISCE

下一篇：第101期抗體試用裝贈(zèng)送活動(dòng) | 數(shù)量有限，只限兩天

免费看一级av一区二区不卡,精品中文字幕第一页在线视频,日韩美女牲a视频,亚洲香蕉一区二区三区,中文字幕不卡八区,亚洲天堂12av,午夜人妻伦理一区二区三区,日韩av电影在线直播,在线观看视频一区二区网站

【6月文獻(xiàn)戰(zhàn)報(bào)】Bioss抗體新增高分文獻(xiàn)精彩呈現(xiàn)